Evaxion Biotech sees cash runway into mid-2026

Cash and cash equivalents as of March 31, 2025, were $17.8 million, as compared to $6.0 million as of December 31, 2024. The significant improvement in our cash position is due to our successful capital markets initiatives in January 2025, and we expect our existing cash and cash equivalents to be sufficient to fund our operating expenses and capital expenditure requirements until mid-2026.